Concepedia

Author

Manfred Welslau

Praxis für Hämatologie und OnkologieORCID

Also Known As

M Welslau, M. Welslau, M.K. Welslau, MANFRED WELSLAU, Manfred Welslau

69

Publications

727

Citations

8

H-Index

23

Concepts

All Affiliations

Praxis für Hämatologie und OnkologieMedizinische Hochschule HannoverKrankenhaus NordwestDana-Farber Cancer Institute
MW

About

Manfred Welslau is an author at Praxis für Hämatologie und Onkologie specializing in radiation oncology, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

153

2

Immunology

3

3

70

3

Pathology

3

3

109

4

Health Sciences

2

2

60

5

Pharmacology

2

2

26

Manfred Welslau

×

8

Publications

649

Citations

8

H-Index

YearCitations

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim,

Journal of Clinical Oncology

2005

439

Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.

Kimberly Blackwell, David Miles, Luca Gianni,

Journal of Clinical Oncology

2012

83

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis,

The Lancet Haematology

2022

44

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

Christian Kollmannsberger, Oliver Rick, Holger Klaproth,

British Journal of Cancer

2002

30

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

Lena Weiss, Meinolf Karthaus, Jorge Riera‐Knorrenschild,

ESMO Open

2022

17

Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: Long-term follow-up of a phase II study

Mathias Rummel, J. Atta, Manfred Welslau,

Journal of Clinical Oncology

2007

16

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study

J. Randolph Hecht, Edith Mitchell, Takayuki Yoshino,

Cancer Management and Research

2015

10

Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas

Mathias Rummel, S. Al-Bartran, Manfred Welslau,

Journal of Clinical Oncology

2005

10

Page 1